Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Q1 Earnings Top Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and -0.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

by Zacks Equity Research

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

by Zacks Equity Research

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

Top Ranked Momentum Stocks to Buy for March 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st

LNTH vs. CLPBY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 22nd

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 26.32% and 6.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data

by Zacks Equity Research

The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).

    Lantheus Holdings (LNTH) Tops Q2 Earnings Estimates

    by Zacks Equity Research

    Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 23.81% and -3.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      New Strong Sell Stocks for March 21st

      by Zacks Equity Research

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

        Should Value Investors Consider Lantheus Holdings (LNTH) Stock?

        by Zacks Equity Research

        Lantheus Holdings is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

          Halyard Health (HYH) Announces Positive Data on COOLIEF

          by Zacks Equity Research

          Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.

            TransEntrix Progresses Toward FDA Approval for Senhance

            by Zacks Equity Research

            TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.

              Surmodics Receives FDA's Approval for PTA Balloon Catheter

              by Zacks Equity Research

              Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                Bruker (BRKR) Strong on Product Launches Amid Currency Woes

                by Zacks Equity Research

                Bruker (BRKR) continues to see solid contributions from NMR and Nano businesses. Also, a raised guidance is indicative of brighter prospects.

                  Myriad Genetics Presents Favorable riskScore Test Data

                  by Zacks Equity Research

                  Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.

                    McKesson to Gain From Distribution Business Amid Pricing Woes

                    by Zacks Equity Research

                    McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.

                      Phibro Animal Health Expands Globally Amid Tough Competition

                      by Zacks Equity Research

                      Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.

                        Thermo Fisher Fundamentals Impressive Amid Tough Competition

                        by Zacks Equity Research

                        Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.

                          Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

                          by Zacks Equity Research

                          Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.

                            NuVasive Launches Breakthrough in MIS Surgery -- LessRay

                            by Zacks Equity Research

                            NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.

                              Genomic Health Ties up With Biocartis, Boosts Oncotype DX

                              by Zacks Equity Research

                              Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.